 Appointments represent Jaguars focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA ACCESSWIRE September 9, 2021 Jaguar Health, Inc. NASDAQ:JAGX Jaguar or the Company today announced the appointment of Karen J. 